CGEM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CGEM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cullinan Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2024 was $-0.69. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.84.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -39.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -23.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Cullinan Therapeutics's EPS without NRI or its related term are showing as below:
During the past 6 years, Cullinan Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -7.10% per year. The lowest was -39.00% per year. And the median was -21.30% per year.
Cullinan Therapeutics's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.84.
Cullinan Therapeutics's EPS (Basic) for the three months ended in Sep. 2024 was $-0.69. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.84.
The historical data trend for Cullinan Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EPS without NRI | Get a 7-Day Free Trial | -1.07 | -1.37 | -1.52 | -1.90 | -3.68 |
Cullinan Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EPS without NRI | Get a 7-Day Free Trial | -0.90 | -0.54 | -0.86 | -0.75 | -0.69 |
For the Biotechnology subindustry, Cullinan Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Cullinan Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics (NAS:CGEM) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Cullinan Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Jennifer Michaelson | officer: See Remarks | C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142 |
Savill Corrine | officer: Acting Chief Business Officer | C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142 |
Nadim Ahmed | director, officer: President and CEO | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Jacquelyn L Sumer | officer: Chief Legal Officer | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
Jeffrey Alan Jones | officer: Chief Medical Officer | ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Jeffrey Trigilio | officer: Chief Financial Officer | C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142 |
David P. Ryan | director | C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Vision Scs F2 | 10 percent owner | 74 GRAND RUE, LUXEMBURG N4 L-1660 |
F2 Bioscience I 2017 Ltd | 10 percent owner | 8, RUE SAINT-LEGER, GENEVA V8 CH 1205 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Anne-marie Martin | director | ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Biotechnology Value Trading Fund Os Lp | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Bvf Partners Os Ltd. | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Mark N Lampert | 10 percent owner | 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
Bvf I Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By Marketwired • 11-04-2024
By GuruFocus News • 11-05-2024
By Marketwired • 04-16-2024
By Marketwired • 09-17-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GlobeNewswire • 06-01-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 05-15-2024
By Marketwired • 11-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.